UCB and Amgen announce positive phase 2 results of CDP7851/AMG785 in patients with post menopausal osteoporosis (PMO).(Financial report)(Clinical report)

On 21 Apr 2011 UCB and Amgen announced positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody CDP7851/AMG785 to placebo in post-menopausal women with low bone mineral density (BMD) for the treatment of post-menopausal osteoporosis (PMO). This Phase 2 study met its primary endpoint, demonstrating significant increases in lumbar spine bone mineral density at month 12 for CDP7851/AMG785 active arms versus the placebo arm. In addition, CDP7851/AMG785 compared positively with the 2 active comparators, teriparatide and alendronate. The overall incidence of adverse events was generally balanced between groups. Consistent with previous studies, injection site …